By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    What Are the Benefits of CBD?
    November 27, 2021
    How to Measure Adult Diapers- The Ultimate Guide to Picking the Right Size
    March 8, 2022
    medicine cabinet
    The Effect Of Finished Dosage Form Manufacturing In New Drugs
    July 5, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    writing medical training manuals
    Important Tips For Writing Medical Training Manuals
    October 28, 2020
    BioPharma Beat logo
    BioPharma Beat: mHealth Apps – to Regulate or Not to Regulate
    May 12, 2015
    Tips for Small Businesses to Reduce Healthcare Costs
    February 5, 2021
    Latest News
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 18, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
    Strengthening Healthcare Systems Through Clinical and Administrative Career Development
    June 13, 2025
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
BusinessFinanceSpecialties

Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials

Deanna Pogorelc
Last updated: October 24, 2013 8:00 am
Deanna Pogorelc
Share
4 Min Read
SHARE

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials.

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials. For startup Alzheon, though, those failures have left behind a trail of valuable clinical and biomarker data that it thinks could lead to hidden treasure.

Alzheon launched today with a plan to scoop up abandoned drug candidates to which it thinks it can apply recent advances in the understanding of Alzheimer’s disease and new diagnostic and prognostic tools to refine the drugs and target them toward more specific groups of patients.

For its first clinical candidate, the Lexington, Massachusetts-based biotech has licensed a prodrug of the small molecule tramiprosate from Bellus Health (formerly Neurochem Inc.) of Quebec, Canada. It was designed to inhibit the formation of amyloid assemblies in the brain that experts have long considered characteristic of the disease.

More Read

Healthcare Associated Infections: What is the Message, and What Can We Do About Them?
Expert Speakers, Opinions Highlight 2013 Bridging the Gap Concussion Conference
Digital Marketing For Healthcare: What You Need To Know
Will Shear Wave Elastography Make an Impact in Liver Disease?
The Pros and Cons of Having Dentures

In the late 2000s, Neurochem took the drug as far as Phase 3 studies involving more than a thousand Alzheimer’s disease patients. It failed to meet the trial’s efficacy endpoints.

But in a retrospective analysis of clinical data, researchers found that the drug seemed to slow atrophy of the hippocampus, a kind of brain damage associated with Alzheimer’s, especially in patients with a gene variation called APOE4.

Alzheon will piggyback on those clues and use a prodrug form of tramiprosate, or an inactive substance that is converted into an active drug inside the body. CEO Dr. Martin Tolar said the prodrug has better properties than its parent drug.

Tolar is a neurologist by training and spent six years in leadership positions at Pfizer before taking on roles at various smaller biotech companies including CoMentis Inc., NormOxys and Knome Inc. Working with him on this new venture is former CoMentis and NormOxys colleague John Hey, a 20-year drug development veteran, and Dr. Mark Versavel, who has led neurology projects at Bayer and Pfizer.

The team will use their combined science and business savvy and the existing clinical data behind ALZ-801 to design a Phase 2 efficacy study around specific subpopulations of Alzheimer’s patients who stand to benefit most from the drug. Tolar said the trial should start next year.

While smaller, more targeted trials should in theory be quicker and more likely to produce positive results than large trials, the trials will still be costly. Tolar declined to disclose details of his company’s initial financing but said his team is working with two private investors with a history success in biopharmaceuticals.

As plans for the trial get underway, Alzheon, which was incorporated in August, is also at work building a pipeline. Tolar said the team is in talks with other companies about in-licensing deals that would bring in other therapeutic approaches that have demonstrated safety and proof-of-concept activity in neurodegenerative disease.

Chief Scientific Officer Hey summed up the company’s long-term strategy in a statement: “Alzheon has unique capabilities to deploy our drug development platform and leverage the clinical knowledgebase from past Alzheimer’s programs to deliver the best of both worlds:  innovative treatments for challenging neurodegenerative diseases and well-designed clinical programs that have a high likelihood of success.”

Follow MedCity News on Facebook and Twitter for more updates.

[Image credit: BigStock Photos]

TAGGED:AlzheimersAlzheon
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

scientist using microscope
When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
Global Healthcare
June 18, 2025
How Therapy Can Improve Your Mental Health and Daily Life
How Therapy Can Improve Your Mental Health and Daily Life
Mental Health
June 18, 2025
healthcare facilities
Preventing Contamination In Healthcare Facilities Starts With Hygiene
Global Healthcare Infographics
June 15, 2025
from gut to glow
From Plate to Wellness: How Everyday Foods Nourish Your Body Inside and Out
Dental health Infographics Specialties
June 15, 2025

You Might also Like

Health careObesity

How Can Parents Prevent Obesity In Children

October 4, 2019

Why Medicare May Be Costing Even More Than You Think

December 4, 2011
sickle cell anemia
Specialties

Five Interesting Facts about Sickle Cell Anemia

September 12, 2017
BusinesseHealthTechnology

How to Find the Best Hosting Provider for Your Medical Website

February 12, 2019
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?